Rize Oncology Company Description

Rize Oncology Inc., a pharmaceutical company, develops oncology therapies for the treatment of soft tissue sarcoma.

The company develops STS-201, a small molecule drug candidate for the treatment of soft tissue sarcoma, as well as other types of cancers and proliferative diseases.

The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025.

Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.

Rize Oncology Inc.

Country	Canada
Founded	2018
Industry	Pharmaceutical Preparations
CEO	Roland Boivin

Contact Details

Address: 301 – 1665 Ellis Street Kelowna, British Columbia V1Y 2B3 Canada
Phone	514-796-2640
Website	rizeoncology.com

Stock Details

Ticker Symbol	RIZE
Exchange	Canadian Securities Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Roland Boivin	Chief Executive Officer
Jim O'Neill	Chief Financial Officer